Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00953732 · ClinicalTrials.gov registry record
A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies
A clinical trial of Actinic Keratosis, sponsored by Peplin.
- Completed
- Registry status
- 117
- Enrollment target
- 20
- Study locations
NCT00953732: Completed study of Actinic Keratosis, sponsored by Peplin.
NCT00953732 is a study of Actinic Keratosis that has completed, run by Peplin. The registered enrollment target is 117 participants, below the 182-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00953732, a study of Actinic Keratosis, has completed, sponsored by Peplin.
- COMPLETED
- Registry status
- 117 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to follow up patients who have achieved complete clearance of AK lesions at the Day 57 visit having completed the PEP005-016 or PEP005-025 studies over a 12 month period to assess both recurrence of Actinic Keratosis (AK) lesions and long term safety in the selected treatment area.
Conditions Studied
Interventions
- DRUG Lesion count
Study Locations (20)
California
- Center for Dermatology - Fremont
- Dermatology Research Associates - Los Angeles
- Dermatology Specialists Inc - Oceanside
- Skin Surgery Medical Group Inc. - San Diego
- Conant Medical Group - San Francisco
Indiana
- Laser Skin Surgery Center of Indiana - Carmel
- Deaconess Clinic, Inc - Evansville
- Dawes Fretein Clinical Research Group, LLC - Indianapolis
- The Indiana Clinical Trials Center, PC - Plainfield
Florida
- North Florida Dermatology Associates, PA - Jacksonville
- University of Miami, Skin Research Camp - Miami
Georgia
- Atlanta Dermatology, Vein & Research Center, LLC - Alpharetta
- Medaphase Inc - Newnan
Illinois
- Altman Dermatology Associates - Arlington Heights
- Glazer Dermatology - Buffalo Grove
Arizona
- Burke Pharmaceutical Research - Hot Springs
Kentucky
- Pedia Research LLC - Owensboro
Michigan
- Hamzavi Dermatology - Fort Gratiot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2009-08 |
| Est. Completion | 2010-10 |
What the finished NCT00953732 record still lists
NCT00953732 is an observational study that tracks outcomes without assigning an intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 182-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Actinic Keratosis appearing as the primary indexed condition, and to 1 intervention - of which Lesion count is the first listed.
NCT00953732 names 20 study sites across 10 states, led by California, Indiana, Florida.
Frequently Asked Questions
What is clinical trial NCT00953732 about?
NCT00953732 is a clinical study titled "A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies". This study is designed to follow up patients who have achieved complete clearance of AK lesions at the Day 57 visit having completed the PEP005-016 or PEP005-025 studies over a 12 month period to assess both recurrence of Actinic Keratosis (AK) lesions and long term safety in the selected treatment ...
What is the current status of trial NCT00953732?
This trial is currently completed. The enrollment target is 117 participants. The study started on 2009-08. Estimated completion is 2010-10.
What conditions does trial NCT00953732 study?
This clinical trial studies the following conditions: Actinic Keratosis.
What interventions are being tested in trial NCT00953732?
The interventions under investigation include: Lesion count (DRUG).
Who is sponsoring clinical trial NCT00953732?
This trial is sponsored by Peplin, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00953732 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Actinic Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00953732's enrollment target sits among peer trials
117 9th of 16 higher than 8 of 16 other Actinic Keratosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Actinic Keratosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans
RECRUITING · Phase 2
-
The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy
RECRUITING · Phase 1
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
ACTIVE NOT RECRUITING · Phase 3
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
ACTIVE NOT RECRUITING · Phase 3
-
Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia